Compare Fidelity National Information Servcs Inc (FIS) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs Natera Inc. Common Stock — how do they compare? Fidelity National Information Servcs Inc trades at $35.89 (market cap $18.15B), while Natera Inc. Common Stock trades at $394.16 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 3.1× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays a 5% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 89 Days and Natera Inc. Common Stock for 0 Days on average.
| FIS | NTRA | |
|---|---|---|
Market Cap | $18.15B | $57.03B |
Volume | 8,219,694 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $67.94 | $425.64 |
52-Week Low | $32.44 | $179.42 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $38.66B | $56.18B |
Dividend Yield | 5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $35.47, up 3.53% with strong earnings beats in recent quarters. The stock shows bearish technical signals despite positive analyst sentiment with 57% buy ratings and a $45.50 consensus target. Fundamentals improved significantly with net income turning positive at $382 million in 2025 after prior losses, while revenue growth is projected to reach $12.2 billion in 2026. Recent business wins include core banking platform adoptions and embedded finance innovations.
FIS presents a compelling value opportunity with low P/E of 5.4 and strong profitability metrics, though technical indicators suggest near-term caution. Key risks include debt management challenges and competitive pressures in financial technology. The 27% upside to analyst targets and ongoing business momentum support a constructive outlook for patient investors.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
